Short answer
RIGEL PHARMACEUTICALS INC (RIGL) filed an 8-K current report with the SEC on April 21, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement). Lilly terminating entire license and collaboration agreement effective June 15, 2026.
RIGEL PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Lilly terminating entire license and collaboration agreement effective June 15, 2026
- Rigel expected to regain full rights to ocadusertib and related RIPK1 programs
- Loss of Lilly collaboration removes potential future milestones and royalties
- CNS program had already terminated in November 2025
- Rigel evaluating termination’s financial and strategic impact
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RIGEL PHARMACEUTICALS INC 8-K filings
Get the next RIGL 8-K as it lands
Follow RIGL for push alerts, or ask the research agent what this filing means.